



PRESS RELEASE

ORABLOC® IN NORTH AMERICA: DISTRIBUTION AGREEMENT SIGNED WITH NDC INC. THUS COMPLETING 100% COVERAGE OF THE US

Capua, 7 May 2015 – **Pierrel Pharma S.r.l.** – a wholly owned subsidiary of Pierrel S.p.A. dedicated to the development, registration and licensing of new drugs and medical devices – and **NDC Inc** – a North American company that is part of the supply chain for health products, and the supply of logistics services and master distribution in an extensive network of distributors for dental products and related medical products – announce the signing on 5 May of a three year agreement for the distribution of the dental anaesthetic Orabloc® (**Articaina Pierrel**) in the US.

NDC Inc is the most recent significant partner joining the distribution platform of Pierrel Pharma in the US, a market now 100% covered by Pierrel, already operating there, by virtue of previous commercial agreements with the leaders in North American distribution such as PattersonDental, Henry Schein, Benco Dental, Dc Dental and Dental Health Products and Safco Dental. These have enabled Pierrel and its leading product Orabloc® to achieve **62 % growth year on year** in 2014.

Architect of the transaction, as on previous occasions, Fabio Velotti, sole Director of Pierrel Pharma, made the following statement in respect of the agreement with **NDC**: *“This agreement marks a very significant moment for the strategy of Pierrel in the US. NDC, in fact, by its scale and business model, fully meets the requirements of our objective to contact the US dentists everywhere. NDC has this potential, with a dense network of local and/or regional distributors that is comprehensive and always available, even in the smallest and most remote parts of the US.”*

* * *

Pierrel S.p.A. is a global supplier to the pharmaceutical, biopharmaceutical and life science industries, specialising in the discovery of medicinal product candidates and the repositioning of existing drugs for new therapeutic indications and clinical research (TCRDO Division), pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years' experience in the pharmaceutical sector, being one of Europe's leading producers of local and dental anaesthetics. The TCRDO Division, working across Europe and the US, is recognised internationally for its research and development into tech based clinical research innovations with its Drug Repositioning and Repurposing System (“DRR2.0”) and Integrated Clinical Development Services (“ICDS”) for the pharmaceutical, biotechnology and biomedical industries. The parent company of the TCRDO Division (**THERAMetrics holding AG**, listed in the Swiss stock exchange) holds the innovative interactive **DRR2.0** platform, which runs on a database of 23 million scientific publications (being virtually all of those available in the field of biomedical literature), of over 4,900 drugs and of 9,400 illnesses. With this data, never before collected in one place and stored in the cloud, the Search and Match algorithm can show a researcher not only the candidate drug but also a detailed road map with indications of possible second medical use. The database can be accessed by molecule or by illness. Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines. The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe.

The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

For further information:

Pierrel S.p.A.

Investor Relations

Dr Raffaele Petrone

e-mail:

Global Consult S.r.l.

Media Relations

Rossana Del Forno

e-mail:



investor.relations@pierrelgroup.com

tel. +39 0823 626 111

fax +39 0823 626 228

areacomunicazione@globalconsultsrl.com

tel. +39 333 6178665